Trial Profile

Phase III bioequivalence trial of ondansetron sublingual spray versus ondansetron sublingual tablet (Zofran).

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 03 Dec 2014

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ondansetron (Primary) ; Ondansetron
Indications Nausea and vomiting
Focus Pharmacokinetics; Registrational
Sponsors INSYS Therapeutics, Inc

Most Recent Events

03 Dec 2014 New trial record
11 Nov 2014 Insys Therapeutics plans to initiate this pivotal trial in 2015, according to a company media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com